Dhansa Labs

Why is Ambey Laboratories Ltd falling/rising?

As of 18-Aug, the stock price of Dhansa Labs Ltd is rising to 21.30, reflecting a 2.16% increase. Despite a 47.28% decline over the past year, the company reported a 20% profit increase, suggesting potential value, though it remains below key moving averages and faces long-term challenges.

As of 18-Aug, the stock price of Dhansa Labs Ltd is rising, currently at 21.30, reflecting a change of 0.45 (2.16%) upward. This increase can be attributed to its performance today, where it has outperformed the sector by 2.38%. Additionally, the stock has shown a positive return of 3.90% over the past week, contrasting with a decline of 1.29% in the Sensex during the same period.<BR><BR>Despite a significant decline of 47.28% over the past year, the company has reported a 20% increase in profits, which may contribute to a perception of value among investors. The stock's valuation is considered very attractive, with a Return on Capital Employed (ROCE) of 6.4 and a low Enterprise Value to Capital Employed ratio of 0.7. This suggests that, despite its recent poor performance, there are underlying financial metrics that could indicate potential for recovery.<BR><BR>However, it is important to note that the stock is still below its longer-term moving averages, specifically lower than the 50-day, 100-day, and 200-day moving averages, which may indicate ongoing challenges. The broader market context shows that the BSE Small Cap index has fallen by 19%, which could also influence investor sentiment. Overall, while the stock is currently rising, it faces significant long-term challenges that investors should consider.

Which are the latest news on Dhansa Labs?

What does Dhansa Labs do?

Dhansa Labs Ltd operates in the Pesticides & Agrochemicals industry as a Micro Cap company, reporting net sales of 41 Cr and a net profit of 2 Cr for the quarter ending March 2026. The company has a market cap of INR 51 Cr and key metrics include a P/E ratio of 9.00 and a debt-equity ratio of 0.38.

Overview:<BR>Dhansa Labs Ltd operates in the Pesticides & Agrochemicals industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as "Ambey Laboratories Private Limited" in 1985 and later converted to a Public Limited Company, changing its name to "Ambey Laboratories Limited" in December 2014. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 41 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 2 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 51 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 9.00<BR>- Industry P/E: 27<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.38<BR>- Return on Equity: 5.78%<BR>- Price to Book: 0.52<BR><BR>Contact Details:<BR>No Company Details Available.

Who are the peers of the Dhansa Labs?

Dhansa Labs' peers include Shivalik Rasayan, Crop Life Scienc, Aristo Bio-Tech, Bhaskar Agrochem, Aimco Pesticides, Super Crop Safe, Adarsh Plant, and Phyto Chem (I). In terms of management risk, growth, and capital structure, most peers exhibit below-average performance, with Crop Life Scienc showing the highest 1-year return at 26.76% and Dhansa Labs at -49.13%.

Peers: The peers of Dhansa Labs are Shivalik Rasayan, Crop Life Scienc, Aristo Bio-Tech, Bhaskar Agrochem, Aimco Pesticides, Super Crop Safe, Adarsh Plant, and Phyto Chem (I).<BR><BR>Quality Snapshot: Excellent management risk is observed at Bhaskar Agrochem, while Average management risk is found at Crop Life Scienc and Aristo Bio-Tech, and the rest have Below Average management risk. Growth is Average at Aristo Bio-Tech, Below Average at Shivalik Rasayan, Crop Life Scienc, Dhansa Labs, Aimco Pesticides, Super Crop Safe, Adarsh Plant, and Phyto Chem (I), and the rest have Below Average growth. Excellent capital structure is noted at Shivalik Rasayan, while Below Average capital structure is found at Crop Life Scienc, Aristo Bio-Tech, Dhansa Labs, Bhaskar Agrochem, Aimco Pesticides, Super Crop Safe, Adarsh Plant, Phyto Chem (I), and the rest.<BR><BR>Return Snapshot: Crop Life Scienc has the highest 1-year return at 26.76%, while Shivalik Rasayan has the lowest at -49.03%, with Dhansa Labs' 1-year return at -49.13%, which is slightly lower than Shivalik Rasayan's. Additionally, the six-month return is negative for Shivalik Rasayan, Dhansa Labs, and Aristo Bio-Tech.

How big is Dhansa Labs?

As of 14th August, Dhansa Labs Ltd has a market capitalization of 51.00 Cr, with recent net sales of 73.36 Cr and a net profit of 2.90 Cr. As of March 2025, shareholder's funds were 76.35 Cr and total assets were 125.79 Cr.

As of 14th August, Dhansa Labs Ltd has a market capitalization of 51.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest two quarters, Dhansa Labs reported Net Sales of 73.36 Cr and a Net Profit of 2.90 Cr. This performance reflects the company's financial activity over the most recent periods.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 76.35 Cr and Total Assets were valued at 125.79 Cr.

How has been the historical performance of Ambey Laborator.?

Ambey Laborator has shown steady growth in net sales, increasing from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25, but faced a decline in profit after tax to 4.78 Cr in Mar'25. The company has negative cash flow from operating activities, indicating liquidity challenges, despite a significant inflow from financing activities.

Answer:<BR>The historical performance of Ambey Laborator shows a steady growth in net sales and total operating income over the past four years, with figures rising from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25. The total expenditure has also increased, reflecting higher raw material costs, which rose from 69.91 Cr in Mar'22 to 118.83 Cr in Mar'25. Operating profit, excluding other income, has fluctuated slightly, peaking at 11.50 Cr in Mar'25, while profit before tax increased to 6.04 Cr in the same period. However, profit after tax saw a decline to 4.78 Cr in Mar'25 from 7.72 Cr in Mar'24. The company's equity capital has grown significantly, reaching 24.95 Cr in Mar'25, and total liabilities increased to 125.79 Cr, driven by a rise in short-term borrowings. Cash flow from operating activities has been negative, indicating challenges in cash generation, while cash flow from financing activities has provided a net inflow of 48.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Ambey Laborator's financial performance has demonstrated a consistent upward trend in net sales, which increased from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25, alongside total operating income that mirrored this growth. The company's total expenditure also rose, primarily due to escalating raw material costs, which climbed from 69.91 Cr to 118.83 Cr over the same period. Operating profit, despite some fluctuations, reached 11.50 Cr in Mar'25, contributing to a profit before tax of 6.04 Cr. However, profit after tax decreased to 4.78 Cr in Mar'25, down from the previous year's 7.72 Cr. The equity capital has notably increased to 24.95 Cr, while total liabilities surged to 125.79 Cr, largely due to a significant rise in short-term borrowings. The cash flow from operating activities has been negative, indicating potential liquidity issues, although cash flow from financing activities has provided a substantial inflow, reflecting the company's reliance on external financing to support its operations.

Is Ambey Laborator. overvalued or undervalued?

As of September 23, 2025, Ambey Laborator is considered very expensive and overvalued with a PE Ratio of 21.92 and an EV to EBITDA of 15.02, significantly underperforming with a -39.55% return compared to the Sensex's -2.97%.

As of 23 September 2025, the valuation grade for Ambey Laborator. has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 21.92, an EV to EBITDA of 15.02, and a ROE of 6.26%. <BR><BR>In comparison to its peers, UPL has a PE Ratio of 38.05 and an EV to EBITDA of 9.17, while P I Industries is also very expensive with a PE of 34.2 and an EV to EBITDA of 24.36. Ambey Laborator.'s valuation appears stretched relative to these peers, highlighting its overvaluation status. Notably, over the past year, the stock has underperformed with a return of -39.55%, contrasting sharply with the Sensex's decline of only -2.97%.

Who are the top shareholders of the Ambey Laborator.?

The top shareholder of Ambey Laborator is Sarina Gupta, holding 68.49% of the shares, with no pledged promoter holdings. Public shareholders include Nakshatra Stressed Assets Fund Scheme I at 1.65% and individual investors collectively holding 22.4%.

The top shareholders of Ambey Laborator are primarily the promoters, with Sarina Gupta holding the highest stake at 68.49%. There are no pledged promoter holdings. In terms of public shareholders, the highest is Nakshatra Stressed Assets Fund Scheme I, which holds 1.65%. Additionally, individual investors collectively hold 22.4% of the shares. There is also one foreign institutional investor (FII) with a very small holding of 0.01%.

What is the technical trend for Ambey?

As of May 19, 2025, Ambey's technical trend is mildly bearish, influenced by daily moving averages and OBV, despite a mildly bullish weekly MACD.

As of 19 May 2025, the technical trend for Ambey has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the daily moving averages and Bollinger Bands are both showing mildly bearish signals. The weekly KST is bearish, and the OBV is also mildly bearish. The Dow Theory shows no trend in both weekly and monthly time frames. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the OBV.

When is the next results date for Ambey?

No Upcoming Board Meetings

Has Ambey declared dividend?

No Dividend History Available